NanoMed has successfully developed a preclinical programme and demonstrated safety and efficacy in animal studies for its Gemcitabine prodrug nanomedicine. Gemcitabine continues to play a central role in chemotherapy treatment for pancreatic cancer. It is also used for the treatment of a range of other cancers, including colorectal and ovarian cancers, non-small cell lung cancer, bladder cancer and metastatic breast cancer, either as a single agent or in combination therapy. Our primary goal is to quickly complete the preclinical pharmacology studies in rodents and address toxicity and efficacy of our Gemcitabine prodrug nanomedicine in a bigger animal model before moving to clinical phase I trials in humans. NanoMed has also completed preclinical toxicity and efficacy studies in mice for two additional prodrug nanomedicines in its pipeline.